ArticleBlood and lymphatic cancer : targets and therapy2025
Neutrophil-Related Genes Predict Prognosis and Contribute to Immunosuppression in Acute Myeloid Leukemia.
Article in Blood and lymphatic cancer : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.Nature communications · 2026Article
- Debio 1562M CD37-targeting ADC is highly active and well tolerated in preclinical models of AML and MDS.Cell reports. Medicine · 2026Article
- Identification and validation of mitochondrial transport and glycolysis-associated prognostic and therapeutic target for lung adenocarcinoma patients.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute myeloid leukemia (AML) prognosis remains challenging due to limited biomarkers integrating tumor microenvironment (TME) dynamics. Neutrophils, key mediators of immune regulation, exhibit dual roles in cancer progression, yet their prognostic significance in AML is poorly defined. This study aimed to construct a neutrophil-related gene signature for AML risk stratification and explore its clinical and immunological implications. Methods: Utilizing transcriptomic and clinical data from TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus), and OHSU cohorts (n=1537), we identified 148 neutrophil-related genes through literature mining. Prognostic genes were selected via univariate Cox regression and LASSO regression (R packages: survival, glmnet). A 5-gene model (CSF3R, BRAF, FFAR2, CD300A, CD37) was validated across internal (TCGA) and external cohorts (GSE10358, GSE14468, OHSU). Immune profiling, drug sensitivity analysis (GDSC database), and TIDE scoring were performed to assess immunotherapy relevance. Results: The neutrophil-based model stratified AML patients into high- and low-risk groups with distinct overall survival (OS, Discussion: This study advances a novel 5-gene prognostic model integrating neutrophil biology into AML risk stratification. CD37, a key regulator of immune evasion, serves as a dual biomarker for prognosis and immunotherapy prediction. While validated across multiple cohorts, experimental studies are warranted to unravel CD37's mechanistic role. Our findings highlight the potential of neutrophil-centric biomarkers in guiding personalized AML therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.